secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-036770
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q2 revenue $9.1M, net loss $22.9M; sells YUTIQ for $82.5M; Phase 2 data due Dec 2023
--------------------------------------------------------------------------------

- Net product revenue fell to $5.3M from $11.3M due to YUTIQ sale and DEXYCU discontinuation.
- Sold YUTIQ franchise to Alimera Sciences for $82.5M cash plus future royalties; retired all bank debt.
- Phase 2 DAVIO 2 (wet AMD) topline data due Dec 2023; no drug-related SAEs reported to date.
- Phase 2 PAVIA (NPDR) fully enrolled (77 patients), topline expected Q2 2024.
- Jay S. Duker appointed President and CEO; Nancy Lurker transitioned to Executive Vice Chair of Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023036770/0000950170-23-036770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023036770/eypt-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-036770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer